These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 18957098)

  • 1. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cocktail of H5N1 COBRA HA vaccines elicit protective antibodies against H5N1 viruses from multiple clades.
    Crevar CJ; Carter DM; Lee KY; Ross TM
    Hum Vaccin Immunother; 2015; 11(3):572-83. PubMed ID: 25671661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
    Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
    Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.
    Holman DH; Wang D; Raja NU; Luo M; Moore KM; Woraratanadharm J; Mytle N; Dong JY
    Vaccine; 2008 May; 26(21):2627-39. PubMed ID: 18395306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus.
    Szécsi J; Gabriel G; Edfeldt G; Michelet M; Klenk HD; Cosset FL
    J Infect Dis; 2009 Jul; 200(2):181-90. PubMed ID: 19505256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.